Captrust Financial Advisors Krystal Biotech, Inc. Transaction History

Captrust Financial Advisors

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 23, 2022	SELL	$48.93 - $73.47 $48 - $73	-1 Reduced 0.64%	155 $10,000
Q2 2022 Aug 16, 2022	BUY	$48.93 - $73.47 $5,039 - $7,567	103 Added 194.34%	156 $10,000
Q1 2022 May 16, 2022	SELL	$51.99 - $72.11 $831 - $1,153	-16 Reduced 23.19%	53 $4,000
Q4 2021 Feb 14, 2022	BUY	$39.81 - $88.24 $2,746 - $6,088	69 New	69 $5,000

309

24.3M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $3.92B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.